Tempus AI (TEM) experienced a seismic shift in its stock price following the release of its Q1 earnings report, which, despite exceeding revenue forecasts, failed to quell market concerns, leading to a 7.2% decline in after-hours trading.
The company reported a revenue of $348.1 million for the quarter ending March 31, reflecting a robust 36.1% increase year-over-year. This figure surpassed the analyst estimates of $345.4 million. However, in a turn of events, the adjusted loss per share improved to $0.13, trumping the $0.20 consensus. Conversely, the GAAP loss broadened, reported at $0.70 per share, which proved disappointing for investors.
After the regular trading session closed at $54.07, the market reacted critically to the team’s full-year revenue guidance, now set between $1.59 and $1.60 billion for 2026. The midpoint of $1.595 billion only marginally aligned with analysts’ expectations of $1.592 billion, failing to excite market participants.
Tempus AI’s net loss ballooned to $125.9 million, up from $68.0 million in the comparable quarter of the previous year. This net loss included $56.3 million attributed to stock compensation and $32.3 million of unrealized losses on marketable securities, raising eyebrows among stakeholders.
The diagnostics segment posted revenue of $261.1 million, marking a 34.7% year-on-year gain. Oncology testing increased by 28%, while the volume of minimal residual disease testing skyrocketed roughly 500% year-over-year, nearing 6,500 tests.
Revenue from the Data & Applications segment also showcased impressive growth, up 40.5% to $87.0 million, driven by a 44.1% increase in the Insights sub-segment. Notably, this marks the third consecutive quarter where bookings exceeded $100 million, indicating a healthy demand for Tempus’ offerings.
Guidance Sparks Caution
The overall revenue guidance for 2026, anticipating approximately 25% annual growth, did not provide the bullish outlook investors were hoping for. Management stated during the earnings call that no additional financing is needed, and forecasted improvements in free cash flow for Q2.
Some areas showed signs of weakness, notably hereditary testing, which is projected to regain a mid-teens growth trajectory later this year amidst changing reimbursement landscapes for MRD ramp-up.
Analyst Sentiment Mixed
Analyst reactions varied widely. Needham maintains a Buy rating with a price target of $75, while Morgan Stanley revised its target down from $85 to $70, retaining an Overweight rating. Guggenheim lowered its target from $95 to $60, also keeping a Buy rating, whereas Jefferies introduced an Underperform rating at a $35 target.
The current consensus among analysts leans toward a “Moderate Buy,” with an average price target resting at $71.36, considerably above the current trading level.
Insider trading activity raised further concerns, with executives selling 563,471 shares worth about $29.8 million over the past 90 days. This selling included key positions from CAO Ryan Bartolucci and EVP Andrew Polovin.
On the institutional front, significant shifts occurred, with Invesco ramping up its position by over 2,900% and Royal Bank of Canada boosting its stake by 201%. The stock’s 52-week trading range stretches from $41.73 to $104.32, with a 200-day moving average standing at $62.91.
As the dust settles from this latest report, stakeholders will watch closely to see how Tempus AI navigates its strategy moving forward amidst a backdrop of mixed financial indicators and cautious market sentiment.
